"Our findings suggest that GLP1s may have beneficial effects on asthma control for people with obesity and this should be explored further." Prof Alan Kaplan, chairperson of the Family Physician Airways Group of Canada and the Observational and Pragmatic Research Institute, said: "Our findings suggest that GLP1-RAs have benefits on asthma control in people with obesity, and this information should contribute to the discussions around the decision to use these drugs." Dr Erika Kennington, head of research and innovation at Asthma and Lung UK, said: "Research has previously shown that people living with obesity who lose weight see improved control of their asthma, so it's encouraging to see this study show this is still the case when the weight loss is driven by drugs, like the new class of weight loss drugs
Thus, there is no right way to treat ASD
Important interaction considerations: Delayed gastric emptying : Mounjaro slows gastric emptying, which may affect the absorption of oral medications
Experiencing hunger while taking Zepbound does not necessarily indicate treatment failure or medication ineffectiveness
If youre curious about whether compounded semaglutide is the right option for you, we encourage you to take our free assessment quiz
Our weight loss program in Santa Ana, California uses GLP-1 medications including Ozempic, Mounjaro, Wegovy, Zepbound and more to help patients lose weight
